TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05731505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory-based education-consulting
Description: Parents in the study groups were provided with training and support in line with their needs in the educational issues specified in the Family Education-Support Booklet for a Child with Cerebral Palsy. The control group was not trained. Research data were collected using the Child and Parent Information Form, Needs Determination Form, Relaxed Behavior Checklist (KDKL), Quality of Life for Children Parent Form (PIDQ) and Self-Efficacy Scale. The comfort and quality of life of the children in the study group and the self-efficacy of the parents were evaluated before the education, 1 month and 3 months after the education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory-based education-consulting
Description: Parents in the study groups were provided with training and support in line with their needs in the educational issues specified in the Family Education-Support Booklet for a Child with Cerebral Palsy. The control group was not trained. Research data were collected using the Child and Parent Information Form, Needs Determination Form, Relaxed Behavior Checklist (KDKL), Quality of Life for Children Parent Form (PIDQ) and Self-Efficacy Scale. The comfort and quality of life of the children in the study group and the self-efficacy of the parents were evaluated before the education, 1 month and 3 months after the education.
Study: NCT04727359

Intervention type: OTHER
Intervention: FIT64b model project
Description: FIT64b model project: The SHI funds AOK Baden-Württemberg and SVLFG (as an agricultural health insurance fund) have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT64b hospital, UKT). This contract encourages the model hospital an alternative treatment of their patients (with the above mentioned SHI fund), for example fewer inpatient and more outpatient treatment.
Study: NCT04732871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
Study: NCT05649189

Intervention type: DIAGNOSTIC_TEST
Intervention: telomere length measure
Description: length of telomere between two groups

Intervention type: DIAGNOSTIC_TEST
Intervention: telomere length measure
Description: length of telomere between two groups
Study: NCT05995847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harmonica playing program plus basic PR care with routine follow-up
Description: The intervention will last for a total of six months. During this period, patients are expected to play the harmonica daily for 30 minutes, five days a week. Additionally, patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic PR care with routine follow-up
Description: These patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months
Study: NCT05571826

Intervention type: BEHAVIORAL
Intervention: telerehabilitation
Description: No specific treatments will be applied. The persons who experienced telerehabilitation interventions will be included.
Study: NCT06547385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Levofolinate Hydrateb
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days
Study: NCT05735405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: Each participant will undergo a complete neuropsychological evaluation, both before and at the end of the clinical trial, with the aim of detecting any changes or improvements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: Each participant will undergo a complete neuropsychological evaluation, both before and at the end of the clinical trial, with the aim of detecting any changes or improvements.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BDNF evaluation
Description: During the first and last clinical trial session, each participant will undergo two blood samples, one before and one at the end of the ride, to check levels of Brain Derived Neurotrophic Factor (BDNF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BDNF evaluation
Description: During the first and last clinical trial session, each participant will undergo two blood samples, one before and one at the end of the ride, to check levels of Brain Derived Neurotrophic Factor (BDNF).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedaling as a moderate intensity aerobic exercise
Description: During each session, each participant will perform 30 minutes of pedaling as a form of moderate intensity physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedaling as a moderate intensity aerobic exercise
Description: During each session, each participant will perform 30 minutes of pedaling as a form of moderate intensity physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: During each session, each participant will carry out 60 minutes of cognitive training through specific exercises for the attentional, executive and working memory functions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: During each session, each participant will carry out 60 minutes of cognitive training through specific exercises for the attentional, executive and working memory functions.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VO2 assessment
Description: To determine the individual moderate intensity for each patient, a VO2 consumption assessment will be made. The examination will be carried out using an exercise bike and a mask for the calculation of metabolic oxygen consumption.~The 3 MET threshold to reach in pedaling will be calculated (to define it of moderate intensity), in order to elicit the release of BDNF.
Study: NCT05735405

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VO2 assessment
Description: To determine the individual moderate intensity for each patient, a VO2 consumption assessment will be made. The examination will be carried out using an exercise bike and a mask for the calculation of metabolic oxygen consumption.~The 3 MET threshold to reach in pedaling will be calculated (to define it of moderate intensity), in order to elicit the release of BDNF.
Study: NCT05436171

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05376020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Densah Burs
Description: Densah Burs will be used in the intervention group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Burs
Description: Conventional Burs will be used in the control group
Study: NCT06334341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Informational Video
Description: A short informational video, tailored to the local Detroit context with themes that will focus on introducing PrEP, stigma surrounding taking PrEP, and potential barriers and how to overcome them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Informational Video
Description: A short informational video, tailored to the local Detroit context with themes that will focus on introducing PrEP, stigma surrounding taking PrEP, and potential barriers and how to overcome them.
Study: NCT05594004

Intervention type: DEVICE
Intervention: Oscillating-rotating electric toothbrush
Description: Oscillating-rotating electric toothbrush used twice daily

Intervention type: DEVICE
Intervention: Sonic electric toothbrush
Description: Sonic electric toothbrush used twice daily

Intervention type: DEVICE
Intervention: Manual toothbrush
Description: Manual toothbrush used twice daily
Study: NCT06333782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental- Genefill Contour®
Description: Genefill Contour® Hyaluronic Acid Injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed comparator - Desirial®Plus
Description: DESIRIAL®PLUS Hyaluronic Acid Injection
Study: NCT05537285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)
Description: active side magnetic coil stimulation applied to individualized target in the left dorsal lateral prefrontal cortex.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)
Description: active side magnetic coil stimulation applied to standardized target in the left dorsal lateral prefrontal cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Accelerated Intermittent Theta Burst Stimulation (Sham)
Description: sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
Study: NCT05604807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia course with virtual reality
Description: dementia virtual reality activity, intergenerational learning, world café teaching method and community practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dementia course with no virtual reality
Description: dementia course, intergenerational learning, world café teaching method and community practice
Study: NCT04770870

Intervention type: DEVICE
Group type: OTHER
Intervention: Hintermann Series H3 Total Ankle Replacement System
Description: Intervention will include receiving the FDA approved Hintermann Series H3 Total Ankle Replacement System, to include a tibial component, a polyethylene inlay, and a talar component.
Study: NCT05650541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPumlonary Management System
Description: The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
Study: NCT05666362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benoxinate hydrochloride 0.4% group
Description: They will receive benoxinate hydrochloride 0.4% immediately before fundus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9% .
Description: They will receive saline 0.9% before fundus examination in each eye .
Study: NCT06385106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real repetitive transcranial magnetic stimulation
Description: The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session. The patients were applied with the coil angled away from the head to reproduce the noise of the stimulation as well as some local sensation
Study: NCT06270589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MF-HIIT
Description: A single bout of 20-min MF-HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s mindful intervals), and finally a 2-min cool-down.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MF-only
Description: A single bout of 20-min intervention mindfulness intervention that includes 5 x 90s mindful intervals separated by sitting rest

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIIT-only
Description: A single bout of 20-min HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s rest intervals), and finally a 2-min cool-down.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sitting rest
Description: Participants will sit in a comfortable chair, placed on the treadmill, while watching a HIIT video without mindfulness instructions for 20 minutes.
Study: NCT06367634

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: injection in NLF
Description: TEOSYAL® PureSense ULTRA DEEP is a sterile, transparent, non-pyrogenic, viscoelastic gel made of HA of non-animal origin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injection in NLF
Description: TEOSYAL® PureSense ULTRA DEEP is a sterile, transparent, non-pyrogenic, viscoelastic gel made of HA of non-animal origin
Study: NCT05629143

Intervention type: PROCEDURE
Group type: OTHER
Intervention: de-prescription of PPI via intermittent scheme
Description: The patients will decrease their intake of PPIs via a de-prescription intermittent scheme. After one month, patients will stop their intake of PPI.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: de-prescription of PPI via on-demand scheme
Description: The patients will decrease their intake of PPIs via a de-prescription on-demand scheme. After one month, patients will stop their intake of PPI.

Intervention type: DRUG
Group type: OTHER
Intervention: Alginate
Description: The patients will stop their intake of PPIs and use alginate. After one month, patients will stop their intake of alginates.
Study: NCT05673733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular stabilization exercises with exergaming training
Description: Group A will receive scapular stabilization exercises with exergaming training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exergaming training
Description: Group B will receive only exergaming training
Study: NCT06277180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery is performed based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, and all 68Ga-TCR-FAPI-avid lesions are resected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery is performed based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, and all 68Ga-TCR-FAPI-avid lesions are resected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: 68Ga-TCR-FAPI PET/CT identified distant metastasis or unresectable lesions, but the patient is still recommended to undergo surgery for debulking or reduce symptoms.
Study: NCT05317507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 100 mg CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 100 mg CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 100 mg CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 100 mg CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 100 mg CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: 100 mg CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04657575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Narcotrend
Description: ECT stimulation within an anaesthesia depth range of 41-64
Study: NCT06445582

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]SDM-8
Description: synaptic vesicle glycoprotein 2 A（SV2A）PET tracer \[18F\]SDM-8
Study: NCT04893187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSS17
Description: SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSS17
Description: SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSS17
Description: SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSS17
Description: SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo.
Study: NCT06046209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens
Description: Daily disposable contact lens for 90 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens
Description: Daily disposable contact lens for 90 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: Monthly replacement contact lens for 90 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: Monthly replacement contact lens for 90 minutes
Study: NCT06509347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preassure release
Description: Preassure release in Flexor digitorum brevis trigger point muscle.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-emision laser
Description: Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
Study: NCT05223166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: Wakix tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
Study: NCT05968690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol will be administered to patients in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol will be administered to patients in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol will be administered to patients in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol will be administered to patients in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone will be administered to patients in cohorts 2, 3, and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone will be administered to patients in cohorts 2, 3, and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone will be administered to patients in cohorts 2, 3, and 4.
Study: NCT05317507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05876559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joyuus Self-care Mobile App
Description: Joyuus is an innovative self-care mobile tool designed to address the needs of underserved women who are at greater risk for adverse postpartum outcomes. It provides the appropriate information, knowledge, and skills to improve postpartum health through self-care, and identifies when it is appropriate to seek care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care is access to typical resources women have access to during postpartum and does not include the Joyuus intervention.
Study: NCT05683951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWKH
Description: Administration of DWKH three times daily
Study: NCT05317507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo